Quality of life is not compromised with intensification of androgen therapy in recurrent prostate cancer

Lancet Oncol. 2018 Oct;19(10):1275-1276. doi: 10.1016/S1470-2045(18)30567-9. Epub 2018 Sep 10.

Authors

Zachary Seymour¹, Daniel Hamstra²

Affiliations

¹ William Beaumont Oakland University Medical School, Radiation Oncology, Dearborn, MI 48124 USA.
² William Beaumont Oakland University Medical School, Radiation Oncology, Dearborn, MI 48124 USA. Electronic address: daniel.hamstra@beaumont.org.

PMID: 30213450
DOI: 10.1016/S1470-2045(18)30567-9

No abstract available

Publication types

Comment

MeSH terms

Androgen Antagonists
Humans
Male
Neoplasm Recurrence, Local
Prostatic Neoplasms*
Prostatic Neoplasms, Castration-Resistant*
Quality of Life
Thiohydantoins

Substances

Androgen Antagonists
Thiohydantoins
apalutamide